EGFR and neoplasm: Currently, several advancing clinical trials are conducted to assess the availability of combining the MET-targeted drugs (MET-TKIs or MET-MAbs) with EGFR TKIs in the treatment of EGFR-mutant tumor with MET-amplification [28, 29].